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1 Abstract
Many natural metabolites have antibacterial, antiviral, or anticancer effects and can be devel-
oped into new drugs. However, working with the microorganisms that produce these products can
be challenging since they are not as well characterized as a model organism like Escherichia coli.
In this paper, we investigate the potential for a cell-free transcription-translation (TX-TL) system
to provide a rapid prototyping platform for characterizing new genetic pathways. We use the vali-
nomycin biosynthesis pathway as a test case, and we show successful heterologous expression of the
heterodimeric valinomycin synthetase (VlmSyn, Vlm1: 374 kDa and Vlm2: 284 kDa) from Strep-
tomyces tsusimaensis within the TX-TL system. Using LC-MS analysis, we find that valinomycin
is produced at low but detectable levels, even when only one out of the three basic precursors is
fed into the system. Our work represents another step towards applying cell-free biosynthesis to
the discovery and characterization of new natural products.
2 Introduction
Natural products have been a key source for new drugs, including antibacterial, antiviral,
and anticancer compounds, for over 30 years [1]. Recent developments in large-scale genetics and
metabolomics have revealed that the chemical space of secondary metabolites still remains largely
unexplored [2]. However, the characterization of new biosynthetic pathways and the small molecules
they produce has been difficult, partly due to the challenges of working with the natural product
producing organisms in the laboratory. Synthetic biology can solve this problem through robust
heterologous expression of the biosynthetic pathways within more well-understood host organisms,
such as Escherichia coli or Saccharomyces cerevisiae.
Cell-free protein expression systems are quickly emerging as a useful tool for synthetic biology
research. They take advantage of native transcription-translation machinery and allow for the
simultaneous in vitro expression of multiple genes in the form of either plasmid or linear DNA
[3,4]. Cell-free systems offer many benefits over cell-based expression, including the elimination of
the need for an appropriate host strain, the ability to easily control specific reaction conditions,
the absence of cell processes that could extraneously influence the behavior of the targeted gene
network, and a greater tolerance for proteins and metabolites toxic to living cells [3]. Reactions in
cell-free systems can be performed in a day, as opposed to one week with in vivo methods, allowing
for more rapid design-build-test cycles [5]. Researchers have recently shown cell-free systems to
have potential in the areas of rapid pathway prototyping [3–5], genetic network design [3,6], and
high-yield protein production [7].
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To investigate the capability of cell-free systems for the characterization of heterologous natural
biosynthetic pathways, we decided to test the biosynthesis pathway for valinomycin in an E. coli -
based cell-free transcription-translation (TX-TL) system developed by Noireaux [8]. Valinomycin is
a dodecadepsipeptide produced by various Streptomyces strains that exhibits a range of antibiotic,
antifungal, and antiparasitic activities [9]. A gene cluster capable of synthesizing valinomycin has
been identified, and it is proposed that its biosynthesis involves a nonribosomal peptide synthetase
(NRPS) called tetramodular valinomycin synthetase (VlmSyn) [10]. NRPSs are challenging to
express in heterologous platforms because of their large sizes (typically ranging from 100 to >300
kDa) and complex structures, but not impossible since two NRPS proteins GrsA and GrsB were
previously reported to show high expression and functionality within an E. coli -based cell-free
system [11]. In addition, researchers were successful in heterologously expressing VlmSyn from
Streptomyces tsusimaensis in a soluble and active form in E. coli [9]. It was found that the in
vivo production of valinomycin in E. coli could occur without precursor feeding or optimization of
cultivation conditions.
VlmSyn is encoded by two distinct genes vlm1 (10,287 bp) and vlm2 (7,968 bp) [9], and they
form a protein “assembly line” of various functional domains organized into four modules (Figure
1). The process requires three basic precursors: α-ketoisovalerate (α-Kiv), pyruvate (Pyr), and
L-Valine (L-Val). α-Kiv is reduced to D-α-hydroxyisovaleric acid (D-Hiv) via the ketoreductase
(KR) domain in Module 1. The epimerase (E) domain in Module 2 transfers L-Val to D-Valine
(D-Val). The KR domain in Module 3 reduces pyruvate to L-Lactate (L-Lac). These three products
(D-Hiv, L-Lac, and D-Val), along with L-Val, are linked to form a tetradepsipeptide basic unit. A
terminal thioesterase (TE) domain oligomerizes and cyclizes the repeating sequence of this basic
unit to form the final valinomycin product [10].
In this report, we demonstrate successful expression of VlmSyn in the TX-TL cell-free system
and show that VlmSyn produces detectable amounts of valinomycin in TX-TL, even when only one
out of the three biosynthetic precursors is fed into the system.
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Figure 1: Proposed model for the biosynthesis of valinomycin. The valinomycin synthetase is divided into
four modules, consisting of domains with adenylation (A), ketoreductase (KR), thiolation (T), condensation
(C), epimerase (E), and thioesterase (TE) functions. Each module incorporates D-Hiv, D-Val, L-Lac, or
L-Val to form a tetradepsipeptide basic unit. After three units are formed, they undergo cleavage and
cyclization to form the final valinomycin product. (Figure inspired by models in [9], [10].)
2
. CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/091520doi: bioRxiv preprint first posted online Dec. 4, 2016; 
3 Results/Discussion
3.1 Obtaining vlm1 and vlm2 genes
We obtained three plasmids that Jaitzig, et al. [9] constructed during their experiments to
reconstitute valinomycin biosynthesis in E. coli (Table S1, Supplementary Material). The first two
plasmids, pVlm1 and pVlm2, contain the vlm1 gene and the vlm2 gene, respectively, controlled
by a plac promoter. As a side experiment, we tried to extract vlm1 and vlm2 from these plasmids
using a PCR protocol modified to account for large amplicon lengths. The modifications included
increasing the template concentration, lengthening the initial denaturation time, increasing the
number of cycles, and lengthening the extension time and extension temperature. In addition, we
tested a gradient of annealing temperatures between 68◦C and 75◦C. Gel electrophoresis showed
strong bands at the correct lengths for vlm1 and vlm2 (Figure 2). However, we also saw multi-
ple nonspecific bands, especially at lower annealing temperatures, which could have resulted from
non-target primer binding or primer-dimer formation. Further tests to determine the optimal PCR
conditions are needed in order to obtain vlm1 and vlm2 in linear form.
The third plasmid, pET15b-sfp, contains the sfp gene controlled by a T7 promoter. sfp en-
codes a phosphopantetheinyl transferase (PPTase) enzyme Sfp from Bacillus subtilis that has been
shown to function in numerous heterologous organisms [9,12]. PPTases are needed to transfer a
phosphopantetheine group during a post-translational modification step for NRPSs like VlmSyn.
Even though E. coli contains native PPTases, it was shown that Sfp is more effective at accepting
Vlm1 and Vlm2 as substrates [9].
75 74.5 72.273.7 70.7 69.4 68.5 68
Vlm1 (Linear) - Gradient PCR
3kb - 
2kb - 
1.5kb - 
1kb - 
0.5kb - 
5kb - 
8kb - 
- 4kb 
- 6kb 
- 10kb 
20kb - 
Annealing
temp. (oC)
Vlm2 (Linear) - Gradient PCR
75 74.5 72.273.7 70.7 69.4 68.5 68
Annealing
temp. (oC)
3kb - 
2kb - 
1.5kb - 
1kb - 
0.5kb - 
5kb - 
8kb - 
20kb - 
- 4kb 
- 6kb 
- 10kb 
Figure 2: Gel electrophoresis analysis for PCR of vlm1 (left) and vlm2 (right). A gradient of annealing
temperatures between 68◦C and 75◦C was tested. Expected sizes for vlm1 and vlm2 linear products are
10,287 bp and 7,968 bp, respectively.
3.2 Creating TX-TL extract from E. coli BJJ01
In order for valinomycin biosynthesis in TX-TL to work, we need to express the PPTase Sfp
in the system. One way to do this is to add the sfp plasmid to every TX-TL reaction, meaning
that each reaction would have three different plasmids. However, resource limitations in TX-TL
could prevent simultaneous expression of all three plasmids [13], especially since the vlm1 and vlm2
genes are so large. To avoid this problem, we decided to create TX-TL extract directly from E.
coli strain BJJ01, which Jaitzig, et al. created by integrating the gene sfp under the control of a
constitutive promoter into the genome of E. coli BL21 Gold.
Since this strain constitutively produces Sfp, the enzymes will already be present in its TX-TL
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extract. We created the extract following the methods described by Sun, et al. [14], with the
exception that we used homogenization instead of bead-beating during the cell lysis step. The
buffer calibration results (Figure 3) show that this new extract (which we named “E34”) requires
a buffer containing 4mM of Mg and 280mM of K, and that its GFP expression can reach over 5000
nM.
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Figure 3: Buffer calibration results for E34 extract, which was made from E. coli strain BJJ01. Concen-
trations for the final buffer are 4mM of Mg and 280mM of K.
3.3 Expressing Vlm1 and Vlm2 in TX-TL
To test Vlm1 and Vlm2 expression in our new E34 extract, we first added pVlm1 and pVlm2
with concentrations varying between 0.001nM and 10nM into separate TX-TL reactions. We used
20nM of IPTG to induce expression and ran the reactions at 25◦C for 12 hours. We decided to use
a temperature lower than the usual 29◦C because it slows down translation, which avoids potential
protein folding issues for the large enzymes. Using SDS-PAGE to assess protein expression, we
found that a large protein above 200kDa is expressed when plasmid concentrations are 1nM or
higher (Figure 4). These are very likely to be our target VlmSyn proteins, since no proteins of that
size are found in the TX-TL extract itself. A Western blot can be performed in order to further
confirm Vlm1 and Vlm2 expression.
Next, we held the plasmid concentrations constant at 1nM and varied the IPTG concentration
and the reaction temperature to find the optimal reaction conditions. Once again, Vlm1 and Vlm2
expression were tested separately, and the reactions were run for 12 hours. The SDS-PAGE results
(Figure 5) show that varying the reaction temperature affects expression more than varying the
IPTG concentration. In fact, as the temperature increases, multiple bands above 200kDa begin
to appear. We believe that since translation speeds up at higher temperatures, errors could occur
during the production of the large proteins, leading to truncated or incomplete sequences that show
up in SDS-PAGE. It may be useful to move the His-tag to the C-terminal and run a Western blot
to confirm whether complete VlmSyn proteins are being produced.
We also see large-size bands in our negative controls (0nM IPTG), which was not expected.
However, these controls do contain 1nM of the Vlm1 or Vlm2 plasmid, so the presence of the large
bands even in the absence of IPTG suggests that the plac promoters could be leaky.
4
. CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/091520doi: bioRxiv preprint first posted online Dec. 4, 2016; 
216 -
132 -
78 -
45.7 -
0 0.001 0.01 0.1 1 10
Plasmid
DNA (nM):
Vlm1
- 198
- 98
- 62
- 49
- 38
kDa kDa
0 0.001 0.01 0.1 1 10
Vlm2
Figure 4: SDS-PAGE gels for Vlm1 (left) and Vlm2 (right) expression in TX-TL extract made from E. coli
strain BJJ01. Different concentrations of pVlm1 and pVlm2 plasmid DNA were tested. Expected sizes are
370kDa for Vlm1 and 284kDa for Vlm2. Bands indicating successful expression of Vlm1 and Vlm2 appear
at 1nM and 10nM concentrations (marked by arrows).
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Figure 5: SDS-PAGE gels for Vlm1 (left) and Vlm2 (right) expression in TX-TL extract made from E. coli
strain BJJ01. pVlm1 and pVlm2 plasmid DNA concentrations were kept constant at 1nM, while reaction
temperature and IPTG concentration were varied. Expected sizes are 370kDa for Vlm1 and 284kDa for
Vlm2.
3.4 Testing a fluorescence assay for valinomycin in TX-TL
Currently, the most reliable quantitative assay for detecting small molecules like valinomycin is
LC-MS, but it requires expensive equipment and has only moderate throughput. Therefore, we in-
vestigated an alternative assay using the fluorescent probe 1-anilino-8-naphthalene sulfonate (ANS).
Valinomycin is an ionophorous antibiotic, meaning that it forms positively charged complexes with
alkali-cations, such as K+, Na+, and Rb+, to affect ion transport in bacteria [15]. When a cation
binds to valinomycin, a conformational change occurs, creating a hydrophobic cavity which ANS
can detect.
Feinstein & Felsenfeld (1971) were able to determine fluorescence emission as a function of
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valinomycin, cation, and ANS concentration in water [15]. We performed a similar experiment
by combining different concentrations of pure, analytical grade valinomycin, KCl, and ANS both
in water and in TX-TL, expecting fluorescence to increase with valinomycin. However, we found
only slight increases in fluorescence intensity when in water, and no increases when in TX-TL
(Figure 6). Further tests are needed, as we may not have used the optimal excitation/emission
wavelengths in these measurements. If successful, this assay will provide a faster, easier way to
quantify valinomycin production.
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Figure 6: Results of ANS fluorescence probe test in water (top) and in TX-TL extract made from E. coli
strain BJJ01 (bottom). Different concentrations of ANS and pure valinomycin were combined, along with
KCl at a constant concentration of 225mM in both tests. Fluorescence was measured using 380/500nm
excitation/emission wavelengths at gain 100.
3.5 Using LC-MS to detect valinomycin in TX-TL
Since the ANS fluorescence assay was unsuccessful, we moved on with LC-MS analysis. We
added pVlm1 and pVlm2 together into a TX-TL reaction, along with the precursor L-Val in purified
form. We also added purified D-Val because, at the time, we mistakenly thought it was a required
precursor. We did not feed in α-ketoisovalerate (α-Kiv) and pyruvate (Pyr) because we were
unable to obtain purified solutions for them at the time of the experiment. After running the
TX-TL reactions at 25◦C for 12 hours, they were analyzed using LC-MS, with a purified 0.5mg/L
valinomycin standard as a positive control. The ion chromatogram (Figure 7) shows that the
case of 1nM pVlm1 and 0.5nM pVlm2 results in the best production, about 0.6mg/L (Table S2,
Supplementary Material). Since the TX-TL samples were diluted 20x prior to LC-MS analysis,
the actual amount of valinomycin produced in this case is about 12mg/L. Adding less than 1nM
of pVlm1 leads to decreased valinomycin production, even when pVlm2 concentrations are higher,
suggesting that Vlm1 expression needs to be higher than Vlm2 expression. Adding 1nM of each
plasmid decreases valinomycin production as well, possibly due to resource limitations preventing
optimal Vlm1 and Vlm2 expression. In the MS spectrum (Figure 8), we see mostly the ammoniated
adduct of valinomycin, analogous to the results in the Jaitzig et al. paper [9], confirming that we
are seeing the correct product.
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Figure 7: Ion chromatograms from LC-MS analysis of valinomycin production in TX-TL extract made
from E. coli strain BJJ01. Not shown: Positive control has a peak similar to the “vlm1 = 0.5nM, vlm2 =
0.5nM” case, while the negative control has no visible peak.
[M+NH4]+
Figure 8: MS spectrum of valinomycin peak for the best-producing “vlm1 = 1nM, vlm2 = 0.5nM” test
case. We mostly see the ammoniated adduct of valinomycin ([M+NH4]
+ m/z 1128.6), similar to what was
seen in the Jaitzig et al. paper [9].
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4 Conclusion
Our results reveal that the pathway for valinomycin biosynthesis (originally from Streptomyces
tsusimaensis) is able to function within a heterologous E. coli -based cell-free TX-TL system. Using
extract created from E. coli BJJ01, which constitutively produces Sfp (needed for post-translational
modifications to the VlmSyn proteins), we were able to detect valinomycin production of up to
12mg/L after the addition of plasmids containing the vlm1 and vlm2 genes. Only one out of the
three precursors for valinomycin biosynthesis, L-Valine, was fed into the system, suggesting that the
other two basic precursors, α-ketoisovalerate and pyruvate, must already be present in the extract.
In the future, more concentration combinations of the plasmids will be tested, along with linear
DNA versions of the genes, which may reduce resource loading and increase yield. Additional tests
should be run to determine optimal precursor feeding concentrations, or whether precursor feeding
is even required. Finally, a faster, easier assay for valinomycin, such as the ANS fluorescent probe,
should be further developed in order to speed up testing of the pathway.
5 Materials/Methods
5.1 Obtaining vlm1 and vlm2 genes
The plasmids used in this study are listed in Table S1 (Supplementary Material). PCR am-
plification of vlm1 and vlm2 was carried out using Phusion Hot Start Flex 2X MasterMix (New
England Biolabs) according to the manufacturer’s protocol with the following modifications: num-
ber of cycles increased to 40, extension time increased to 1 min/kb, annealing time increased to 1
min, initial denaturation time lengthened to 2 min, extension temperature increased to 75◦C, and
annealing temperatures varied between 68◦C and 75◦C on a gradient. Primers for PCR are listed
in Table S3 (Supplementary Material) and were ordered from Integrated DNA Technologies. PCR
products were analyzed on a 1% agarose gel.
5.2 Creating TX-TL extract from E. coli BJJ01
The strain E. coli BJJ01 was obtained from Jaitzig, et al. [9] as a glycerol stock. A small
sample was streaked onto LB agar (no antibiotic) and incubated overnight at 37◦C prior to extract
preparation. The extract was made following the methods described by Sun, et al. [14], with the
exception that we used homogenization instead of bead-beating during the cell lysis step. Buffer
for this extract required 4mM of Mg-glutamate and 280mM of K-glutamate.
5.3 Expressing Vlm1 and Vlm2 in TX-TL
TX-TL reactions were conducted following the protocols described in [14]. When possible,
DNA and inducers (such as IPTG) that were to remain at constant concentrations were added to a
mastermix of extract and buffer to ensure uniform distribution. TX-TL reactions were conducted
in PCR tubes at the standard volume of 10uL per reaction and incubated for 12 hours in a PCR
machine. To prepare samples for SDS-PAGE, we mixed 1uL of the TX-TL reaction sample with
10uL of 1X LDS buffer and then heated the mixture at 70◦C for 10 min. Samples were loaded into
pre-made Bolt 4-12% Bis-Tris Plus Gels (Thermo Fisher Scientific Inc.) and run at 200V for 30-40
min. Gels were stained with SimplyBlue SafeStain (Thermo Fisher Scientific Inc.) following the
manufacturer’s protocol.
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5.4 Testing a fluorescence assay for valinomycin in TX-TL
The fluorescent probe 1-anilino-8-naphthalene sulfonate (ANS) was ordered from Sigma-Aldrich
(Product Number A1028), along with ready-made valinomycin standard (∼1 mg/mL in DMSO, 0.2
um filtered, Product Number V3639). Initial stock solutions of ANS and valinomycin were obtained
by diluting with water; different concentrations were then obtained from these stocks by further
diluting with either water or TX-TL depending on the experiment. Total volume per reaction was
10uL. Reactions were conducted in a 384-well plate, and fluorescence was measured at 29◦C using
a plate reader with 380/500nm excitation/emission wavelengths at gain 100. Three consecutive
measurements were taken for each reaction.
5.5 Using LC-MS to detect valinomycin in TX-TL
We obtained L-Valine (reagent grade, ≥98%, Product Number V0500) and D-Valine (≥98%,
Product Number 855987) from Sigma-Aldrich. TX-TL reactions were conducted following the pro-
tocols described in [14], in PCR tubes at the standard volume of 10uL per reaction, and incubated
at 25◦C for 12 hours in a PCR machine. Ten repeats were made for each reaction in order to
have enough volume for LC-MS analysis. After completion of the TX-TL run, the repeats were
combined and diluted 1:20 with water. LC-MS analysis of extracts was performed with the Waters
Acquity UPLC-TOF MS system. For UPLC separation, we used a 2.1 × 50 mm, 1.8 um column
with water +0.1% HCOOH (v/v) as eluent A and acetonitrile +0.1% HCOOH (v/v) as eluent B.
Samples were separated at a flow rate of 0.3 mL/min with a linear gradient from 5 to 100% B
over 2.5 min, an isocratic elution at 100% B for 5.5 min and a linear gradient from 100 to 5% B
over 4 min. In order to quantify valinomycin produced in the TX-TL reactions, a purified 0.5mg/L
valinomycin standard was used as a basis for comparison.
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Table S1: Plasmids used in this study.
Plasmid Description Source
pVlm1 plac CTU promoter, SD T7 RBS, N-terminal His-tag, attB Jaitzig et al.[9]
sites, lacI, pMB1 ori, CmR, vlm1
pVlm2 plac CTU promoter, SD T7 RBS, N-terminal His-tag, attB Jaitzig et al.[9]
sites, lacI, parB locus, pMB1 ori, AmpR, vlm2
pET15b-sfp pT7 promoter, His-sfp, lacI, rop, T7 terminator, pMB1 ori Jaitzig et al.[9]
Table S2: LC-MS results.
Sample
No.
Sample Description Area RT S/N Response Conc. Height
Inj.
Vol
1 Pos. ctrl (0.5 mg/L) 267.8 4 2163.746 267.784 0.5 5898 10
2 Vlm1 (1nM) + Vlm2 (1nM) 85.3 4 22.935 85.313 0.159 2240 10
3 Vlm1 (0.5nM) + Vlm2 (0.5nM) 57.6 3.99 32.64 57.647 0.108 1208 10
4 Vlm1 (1nM) + Vlm2 (0.5nM) 288 3.99 110.808 287.96 0.538 6406 10
5 Vlm1 (0.5nM) + Vlm2 (1nM) 6.6 3.99 2.763 6.608 0.012 174 10
6 Vlm1 (0.5nM) + Vlm2 (1nM) 6.9 3.96 7.642 6.864 0.013 176 10
7 Vlm1 (1nM) + Vlm2 (0.5nM) 341.1 3.97 250.685 341.084 0.637 8959 10
8 Vlm1 (0.5nM) + Vlm2 (0.5nM) 128.5 3.97 52.73 128.499 0.24 3369 10
9 Vlm1 (1nM) + Vlm2 (1nM) 176.1 3.97 73.212 176.086 0.329 4010 10
10 Pos. ctrl (0.5 mg/L) 463.5 3.97 50.802 463.523 0.865 10345 10
11 Neg. ctrl 0.1 3.99 0.009 0.129 0 3 10
Table S3: Primers used in this study.
Primer Name Sequence Target Anneal Temp.
TZ vlm full FWD TGGAAAGCGGGCAGTGAGC vlm1, vlm2 71◦C
TZ vlm1 full REV GCTAGGGCGCTGGCAAGTGTAG vlm1 71◦C
TZ vlm2 full REV TACAGAGACGGACACAGGGAGGTG vlm2 71◦C
11
. CC-BY-NC-ND 4.0 International licensepeer-reviewed) is the author/funder. It is made available under a
The copyright holder for this preprint (which was not. http://dx.doi.org/10.1101/091520doi: bioRxiv preprint first posted online Dec. 4, 2016; 
